# An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.

> **NCT00996268** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 46 (actual)

## Conditions studied

- Cardiovascular Disease

## Interventions

- **DRUG:** GSK2212836
- **DRUG:** GSK2212836

## Key facts

- **NCT ID:** NCT00996268
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-15
- **Primary completion:** 2010-01-04
- **Final completion:** 2010-01-04
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2017-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996268

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996268, "An Open-label Single Dose Randomized, Parallel Group Study Followed by Single-blind Repeat Dosing, to Compare the Relative Bioavailability of GSK2212836.". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00996268. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*